Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 47, (18314-18319) DOI: 10.1073/pnas.0803094105);Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 47, 2008, Pages 18314-18319

  Bose, Rathindra N ^a,b   Maurmann, Leila ^b,c   Mishur, Robert J ^b   Yasui, Linda ^b   Gupta, Shefalika ^b   Grayburn, W Scott ^b   Hofstetter, Heike ^b   Milton, Tara ^b  

^a OHIO UNIVERSITY   (United States)

^b NORTHERN ILLINOIS UNIVERSITY   (United States)

^c KANSAS STATE UNIVERSITY   (United States)

Author keywords

Phosphate coordinated platinum anticancer agents; Protein binding platinum anticancer agents

Indexed keywords

(1,2 CYCLOHEXANEDIAMINE)(DIHYDROGEN PYROPHOSPHATO)PLATINUM; CARBOPLATIN; CISPLATIN; DOUBLE STRANDED DNA; FAS ANTIGEN; PLATINUM COMPLEX; PROTEIN BAK; PROTEIN BAX; PYROPHOSPHORIC ACID DERIVATIVE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA ISOLATION; DRUG MECHANISM; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE; OVARY CANCER; PRIORITY JOURNAL;

EID: 57449101880     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811947106     Document Type: Erratum

References (41)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: A new class of potent antitumour agents. Nature 222:385-386.
2. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev 4:307-320.
3. Hall MD, Hambley TW (2002) Platinum(IV) antitumor compounds: Their bioinorganic chemistry. Coord Chem Rev 232:49-67.
4. Hsu DS, et al (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350-4357.
5. Raaphorst GP, Wang G, Stewart D, Ng CE (1996) Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Int J Rad Biol 69:623-631.
6. Sorenson CM, Eastman A (1988) Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: Role of G2 arrest and DNA double-strand breaks. Cancer Res 48:4484-4488.
7. Eastman A (1990) Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280.
8. Vaisman A, Varchenko M, Said I, Chaney SG (1997) Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27:54-64.
9. 2{d(pGpG}], the principal adduct formed by cis-diamminedichloroplatinum(II) with DNA. J Am Chem Soc 110:7368-7738.
10. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270:1842-1844.
11. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro platinum(II) and cis-diammine-(1,1- cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979.
12. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235.
13. Mishur RJ, Zheng C, Gilbert T, Bose RN (2008) Synthesis and characterization of platinum(II)- and platinum(IV)-pyrophosphato complexes. Inorg Chem 47:7972-7982.
14. Bose RN, Viola RE, Cornelius RD (1984) Phosphorus-31 NMR and kinetic studies of the formation of ortho-, pyro-, and triphosphato complexes of cis-dichlorodiammineplatinum(II). J Am Chem Soc 106:3336-3344.
15. Zheng H, Fink D, Howell SB (1997) Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin. Clin Cancer Res 3:1157-1165)
16. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406.
17. Centerwall CR, et al (2006) Modification and uptake of a cisplatin carbonato complex by Jurkat cells. Mol Pharmacol 70:348-355.
18. Li D, Bose RN (1992) Insight into the preferential intrastrand binding to adjacent guanine bases in DNA by platinum. J Chem Soc Chem Comm 1596-1598.
19. +. Chem Eur J 2:1283-1291.
20. Volckova E, Dudones LP, Bose RN (2002) HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: Implications of dominant platinum-thiol binding to its anticancer action. Pharmacol Res 19:124-131.
21. Parker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87:772-777.
22. Goodwin PK, et al (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase in glutathione synthesis. Proc Natl Acad Sci USA 89:3070-3074.
23. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of anticancer drug cisplatin mediated by copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302.
24. Guo Y, Smith K, Petris MJ (2004) Cisplatin stabilizes multimeric complex of the human Ctr1 copper transporter: Requirement for the extracellular methionine rich clusters. J Biol Chem 279:46393-46399.
25. Bose RN, Ghosh SK, Moghaddas S (1997) Reaction of biological thiols with cis-diamminedichloroplatinum(II): Implications to the extent of platinum-DNA binding. J Inorg Biochem 199-205.
26. Bose RN, Li D, Basu S (1995) Facile formation of a cisplatin-nonapeptide complex of human polymerase-alpha origin. J Chem Soc Chem Comm 1731-1732.
27. Bhattacharyya N, Banerjee S (2003) Analysis of alterations in base-excision repair gene in lung cancer. Methods Mol Med 74:413-438.
28. Bhattacharyya N, Chen HW, Liming W, Banerjee S (2002) Heterogeneity in expression of DNA polymerase beta and DNA repair activity in human tumor cell lines. Gene Expression 10:115-123.
29. Hoffmann JS, et al. (1995) DNA Polymerase B bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 92:5356-5360.
30. Rebbaa A, Zheng X, Chu F, Mirkin BL (2006) The role of histone acylation versus DNA damage in drug induced senescence and apoptosis. Cell Death Differ 13:1960-1967.
31. Lacour S, et al (2004) Cisplatin-induced CD95 redistribution into membrane lipid rafts of Ht29 human colon cancer cells. Cancer Res 64:3593-3598.
32. Rebillard A, et al (2007) Cisplatin-induced apoptosis involves membrane fludification via inhibition of NHEI1 in human colon cancer, Cancer Res 67:7865-7874.
33. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT (1999) Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274: 7987-7992.
34. Burger H, Nooter K, Boersma AWM, Kortland CJ, Stoter G (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73:592-599.
35. Bose RN (2002) Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2:103-111.
36. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR (2007) Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci USA 104:4365-4370.
37. Deng J, et al (2007) Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67:11867-11875.
38. Darnell JE, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
39. LaCasse EC, et al (2005) Application of XIAP antisense to cancer and other proliferative disorders: Development of AEG35156/GEM640. Ann NY Acad Sci 1058:215-234.
40. Campàs C, et al (2003) Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101:3674-3680.
41. McGahan MC, Tyczkowska K (1987) The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy. Spectrochim Acta 42B:665-668.